GILD
Price
$147.50
Change
-$1.55 (-1.04%)
Updated
Oct 1 closing price
Capitalization
188.73B
21 days until earnings call
Intraday BUY SELL Signals
SNY
Price
$40.67
Change
-$0.56 (-1.36%)
Updated
Oct 1 closing price
Capitalization
98.14B
29 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

GILD vs SNY

GILD vs SNY Comparison Chart in %
View a ticker or compare two or three
VS
GILD vs. SNY commentary
Oct 02, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GILD is a Hold and SNY is a Buy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
GILD vs SNY: Fundamental Ratings
GILD
SNY
OUTLOOK RATING
1..100
8417
VALUATION
overvalued / fair valued / undervalued
1..100
9
Undervalued
43
Fair valued
PROFIT vs RISK RATING
1..100
11100
SMR RATING
1..100
9681
PRICE GROWTH RATING
1..100
3970
P/E GROWTH RATING
1..100
7112
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GILD's Valuation (9) in the Biotechnology industry is somewhat better than the same rating for SNY (43) in the Pharmaceuticals Major industry. This means that GILD’s stock grew somewhat faster than SNY’s over the last 12 months.

GILD's Profit vs Risk Rating (11) in the Biotechnology industry is significantly better than the same rating for SNY (100) in the Pharmaceuticals Major industry. This means that GILD’s stock grew significantly faster than SNY’s over the last 12 months.

SNY's SMR Rating (81) in the Pharmaceuticals Major industry is in the same range as GILD (96) in the Biotechnology industry. This means that SNY’s stock grew similarly to GILD’s over the last 12 months.

GILD's Price Growth Rating (39) in the Biotechnology industry is in the same range as SNY (70) in the Pharmaceuticals Major industry. This means that GILD’s stock grew similarly to SNY’s over the last 12 months.

SNY's P/E Growth Rating (12) in the Pharmaceuticals Major industry is somewhat better than the same rating for GILD (71) in the Biotechnology industry. This means that SNY’s stock grew somewhat faster than GILD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GILDSNY
RSI
ODDS (%)
Bearish Trend 2 days ago
55%
Bullish Trend 2 days ago
65%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
55%
Bullish Trend 2 days ago
50%
Momentum
ODDS (%)
Bullish Trend 2 days ago
67%
Bearish Trend 2 days ago
51%
MACD
ODDS (%)
Bearish Trend 2 days ago
35%
Bearish Trend 2 days ago
61%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
45%
Bearish Trend 2 days ago
52%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
65%
Bearish Trend 2 days ago
46%
Advances
ODDS (%)
Bullish Trend 4 days ago
64%
Bullish Trend 4 days ago
51%
Declines
ODDS (%)
Bearish Trend 2 days ago
48%
Bearish Trend 8 days ago
50%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
56%
Aroon
ODDS (%)
Bullish Trend 2 days ago
60%
Bearish Trend 2 days ago
51%
COMPARISON
Comparison
Oct 02, 2026
Stock price -- (GILD: $147.50 vs. SNY: $40.67)
Brand notoriety: GILD: Notable vs. SNY: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: GILD: 74% vs. SNY: 201%
Market capitalization -- GILD: $188.73B vs. SNY: $98.14B
GILD [@Pharmaceuticals: Major] is valued at $188.73B. SNY’s [@Pharmaceuticals: Major] market capitalization is $98.14B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $4.8K to $1.06T. The average market capitalization across the [@Pharmaceuticals: Major] industry is $200.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GILD’s FA Score shows that 2 FA rating(s) are green while SNY’s FA Score has 1 green FA rating(s).

  • GILD’s FA Score: 2 green, 3 red.
  • SNY’s FA Score: 1 green, 4 red.
According to our system of comparison, GILD is a better buy in the long-term than SNY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GILD’s TA Score shows that 3 TA indicator(s) are bullish while SNY’s TA Score has 4 bullish TA indicator(s).

  • GILD’s TA Score: 3 bullish, 4 bearish.
  • SNY’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, GILD is a better buy in the short-term than SNY.

Price Growth

GILD (@Pharmaceuticals: Major) experienced а -1.46% price change this week, while SNY (@Pharmaceuticals: Major) price change was -0.66% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -2.29%. For the same industry, the average monthly price growth was -7.43%, and the average quarterly price growth was +9.05%.

Reported Earning Dates

GILD is expected to report earnings on Oct 22, 2026.

SNY is expected to report earnings on Oct 30, 2026.

Industries' Descriptions

@Pharmaceuticals: Major (-2.29% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

View a ticker or compare two or three
GILD
Daily Signal:
Gain/Loss:
SNY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DTSS0.830.03
+3.88%
Datasea Intelligent Technology Ltd.
ALK39.490.79
+2.04%
Alaska Air Group
SBSI30.490.41
+1.36%
Southside Bancshares Inc
PYPL53.060.53
+1.01%
PayPal Holdings
EVGO1.26N/A
N/A
EVgo

GILD and

Correlation & Price change

A.I.dvisor indicates that over the last year, GILD has been loosely correlated with AMGN. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if GILD jumps, then AMGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GILD
1D Price
Change %
GILD100%
-1.04%
AMGN - GILD
46%
Loosely correlated
-3.38%
AZN - GILD
39%
Loosely correlated
-2.33%
JNJ - GILD
39%
Loosely correlated
-2.30%
ABBV - GILD
39%
Loosely correlated
-0.63%
BIIB - GILD
38%
Loosely correlated
-1.35%
More

SNY and

Correlation & Price change

A.I.dvisor indicates that over the last year, SNY has been loosely correlated with PFE. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if SNY jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SNY
1D Price
Change %
SNY100%
-1.36%
PFE - SNY
47%
Loosely correlated
-1.40%
MRK - SNY
42%
Loosely correlated
-1.03%
BIIB - SNY
41%
Loosely correlated
-1.35%
GILD - SNY
38%
Loosely correlated
-1.04%
AMGN - SNY
37%
Loosely correlated
-3.38%
More